1. Home
  2. PLSE vs LQDA Comparison

PLSE vs LQDA Comparison

Compare PLSE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

N/A

Current Price

$58.29

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

LQDA

Liquidia Corporation

N/A

Current Price

$47.98

Market Cap

4.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLSE
LQDA
Founded
2014
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.0B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
PLSE
LQDA
Price
$58.29
$47.98
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
★ $66.67
$54.38
AVG Volume (30 Days)
364.5K
★ 3.9M
Earning Date
11-05-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 51.81
EPS
N/A
★ 1.26
Revenue
N/A
★ $158,320,000.00
Revenue This Year
$480.71
$357.27
Revenue Next Year
$177.98
$1.34
P/E Ratio
★ N/A
$35.40
Revenue Growth
N/A
★ 1031.18
52 Week Low
$12.56
$22.31
52 Week High
$58.90
$93.61

Technical Indicators

Market Signals
Indicator
PLSE
LQDA
Relative Strength Index (RSI) 62.63 55.64
Support Level $49.01 $35.00
Resistance Level N/A $63.46
Average True Range (ATR) 3.63 3.10
MACD 0.41 1.61
Stochastic Oscillator 89.60 77.29

Price Performance

Historical Comparison
PLSE
LQDA

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: